PACS

PACS Group, Inc. (PACS) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2024. PACS Group, Inc. is a leading post-acute healthcare company operating 220 skilled nursing facilities (SNF) and assisted living facilities across nine states. As of June 30, 2024, the Company operated approximately 24,480 skilled nursing beds and 880 assisted living beds. The Company completed its Initial Public Offering (IPO) on April 15, 2024, listing on the New York Stock Exchange under the symbol "PACS."

Key Financial Metrics

Note: Total Debt calculated as Lines of Credit ($248,000) + Long-term debt net of fees ($227,107) + Current maturities ($15,745) = $490,852. The table above reflects the sum of Lines of Credit and Long-term debt less current maturities for a conservative view, or $475,107 if excluding current maturities from the long-term line. Total Liabilities were $3.32 billion.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 29.1% year-over-year (Q2) and 30.5% (YTD) to $981.8 million and $1.92 billion, respectively. This was driven by a 19.2% increase in operational beds and a 24.8% increase in patient days.
• Profitability Decline (Q2): Operating income collapsed to $710 thousand in Q2 2024 from $49.5 million in Q2 2023. Net income turned to a loss of $10.9 million compared to a profit of $21.2 million in the prior year quarter.
• Expense Surge: General and administrative (G&A) expenses increased 130.3% in Q2 to $144.4 million. This was primarily due to $90.9 million in stock-based compensation expense related to the IPO, which was not present in the prior year.
• Payor Mix Shift: Skilled mix by revenue decreased to 51.2% in Q2 2024 from 58.0% in Q2 2023, reflecting a higher proportion of lower-reimbursing Medicaid patients in new facilities.
• Capital Structure: The Company raised $414.2 million in net proceeds from its IPO in April 2024. Approximately $370 million of these proceeds were used to repay amounts outstanding under its credit facility, reducing lines of credit from $520 million (Dec 2023) to $248 million (June 2024).

Guidance, Outlook, and Risks

• Outlook: Management expects G&A expenses to increase on an absolute dollar basis due to public company costs but anticipates leveraging these expenses over time as revenue grows. The Company continues to pursue an acquisition strategy focused on underperforming facilities to transform them into higher-acuity operations.
• Regulatory Risks: Significant risks include the implementation of the new CMS Minimum Staffing Standards Final Rule (effective August 2024), which mandates 24/7 RN presence and specific nursing hours per resident day. Non-compliance could result in fines or loss of certification.
• Reimbursement Risks: The Company relies heavily on Medicare (37.5% of revenue) and Medicaid (38.1% of revenue). Changes in reimbursement rates, cost-containment initiatives, or the unwinding of Medicaid continuous enrollment protections pose material risks.
• Operational Risks: The Company faces risks related to the integration of new acquisitions, which often have regulatory and clinical challenges. Additionally, the Company is subject to litigation risks common in the healthcare industry, including professional liability and wage/hour claims.
• Unusual Items: The Q2 results were significantly impacted by non-cash stock-based compensation ($90.9 million). Adjusted EBITDA for the six months ended June 30, 2024, was $188.2 million.

Investor Verification Checklist

• Stock-Based Compensation Impact: Verify the sustainability of profitability once the one-time IPO-related stock compensation expense is excluded from future periods.
• Staffing Rule Compliance: Assess the financial impact of the new federal minimum staffing standards (3.48 hours per resident day) on labor costs, given the Company's heavy reliance on Medicaid reimbursement.
• Payor Mix Trends: Monitor the "Skilled Mix" metric closely; a continued decline toward Medicaid-heavy mixes could compress margins despite revenue growth.
• Acquisition Integration: Review the performance of "New" facilities (purchased
• Debt Covenants: Confirm continued compliance with the Amended and Restated 2023 Credit Facility covenants, specifically the debt-to-income ratio (max 3.00:1.00) and interest/rent coverage ratio (min 1.10:1.00).